Following the recommendation from the independent study’s Executive Committee and the significant impact of COVID-19 on patient recruitment, Vifor has decided to alter the primary endpoint of Veltassa’s phase-IIIb DIAMOND study. The drug will now target a smaller patient base, thereby lowering its sales potential in the mid-term. However, the data read-out from the trials could be out earlier than expected.
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Veltassa’ DIAMOND study amended
- Published:
24 Jun 2021 -
Author:
Sumit Sayal -
Pages:
2
Following the recommendation from the independent study’s Executive Committee and the significant impact of COVID-19 on patient recruitment, Vifor has decided to alter the primary endpoint of Veltassa’s phase-IIIb DIAMOND study. The drug will now target a smaller patient base, thereby lowering its sales potential in the mid-term. However, the data read-out from the trials could be out earlier than expected.